BACKGROUND: Small clinical studies of granulocyte colony-stimulating factor (G-CSF) therapy for cardiac repair after acute myocardial infarction (MI) have yielded divergent results. The effect of G-CSF therapy on left ventricular (LV) function and structure in these patients remains unclear. METHODS: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL, and the Cochrane CENTRAL database of controlled clinical trials (July 2007) for randomized controlled trials of G-CSF therapy in patients with acute MI. We conducted a fixed-effects meta-analysis across 8 eligible studies (n = 385 patients). RESULTS: Compared with controls, G-CSF therapy increased LV ejection fraction (EF) by 1.09%, increased LV scar size by 0.22%, decreased LV end-diastolic volume by 4.26 mL, and decreased LV end-systolic volume by 2.50 mL. None of these effects were statistically significant. The risk of death, recurrent MI, and in-stent restenosis was similar in G-CSF-treated patients and controls. Subgroup analysis revealed a modest but statistically significant increase in EF (4.73%, P < .0001) with G-CSF therapy in studies that enrolled patients with mean EF <50% at baseline. Subgroup analysis also showed a significant increase in EF (4.65%, P < .0001) when G-CSF was administered relatively early (< or =37 hours) after the acute event. CONCLUSIONS: Granulocyte colony-stimulating factor therapy in unselected patients with acute MI appears safe but does not provide an overall benefit. Subgroup analyses suggest that G-CSF therapy may be salutary in acute MI patients with LV dysfunction and when started early. Larger randomized studies may be conducted to evaluate the potential benefits of early G-CSF therapy in acute MI patients with LV dysfunction.
BACKGROUND: Small clinical studies of granulocyte colony-stimulating factor (G-CSF) therapy for cardiac repair after acute myocardial infarction (MI) have yielded divergent results. The effect of G-CSF therapy on left ventricular (LV) function and structure in these patients remains unclear. METHODS: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL, and the Cochrane CENTRAL database of controlled clinical trials (July 2007) for randomized controlled trials of G-CSF therapy in patients with acute MI. We conducted a fixed-effects meta-analysis across 8 eligible studies (n = 385 patients). RESULTS: Compared with controls, G-CSF therapy increased LV ejection fraction (EF) by 1.09%, increased LV scar size by 0.22%, decreased LV end-diastolic volume by 4.26 mL, and decreased LV end-systolic volume by 2.50 mL. None of these effects were statistically significant. The risk of death, recurrent MI, and in-stent restenosis was similar in G-CSF-treated patients and controls. Subgroup analysis revealed a modest but statistically significant increase in EF (4.73%, P < .0001) with G-CSF therapy in studies that enrolled patients with mean EF <50% at baseline. Subgroup analysis also showed a significant increase in EF (4.65%, P < .0001) when G-CSF was administered relatively early (< or =37 hours) after the acute event. CONCLUSIONS:Granulocyte colony-stimulating factor therapy in unselected patients with acute MI appears safe but does not provide an overall benefit. Subgroup analyses suggest that G-CSF therapy may be salutary in acute MI patients with LV dysfunction and when started early. Larger randomized studies may be conducted to evaluate the potential benefits of early G-CSF therapy in acute MI patients with LV dysfunction.
Authors: Hüseyin Ince; Michael Petzsch; Hans Dieter Kleine; Heike Eckard; Tim Rehders; Detlev Burska; Stephan Kische; Mathias Freund; Christoph A Nienaber Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Stephen G Ellis; Marc S Penn; Brian Bolwell; Mario Garcia; Matthews Chacko; Thomas Wang; Kelly J Brezina; Gerry McConnell; Eric J Topol Journal: Am Heart J Date: 2006-12 Impact factor: 4.749
Authors: David A Hess; Krysta D Levac; Francis N Karanu; Michael Rosu-Myles; Martin J White; Lisa Gallacher; Barbara Murdoch; Michael Keeney; Pamela Ottowski; Ronan Foley; Ian Chin-Yee; Mickie Bhatia Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Ahmed Abdel-Latif; Roberto Bolli; Imad M Tleyjeh; Victor M Montori; Emerson C Perin; Carlton A Hornung; Ewa K Zuba-Surma; Mouaz Al-Mallah; Buddhadeb Dawn Journal: Arch Intern Med Date: 2007-05-28
Authors: Benjamin Hibbert; Bradley Hayley; Robert S Beanlands; Michel Le May; Richard Davies; Derek So; Jean-François Marquis; Marino Labinaz; Michael Froeschl; Edward R O'Brien; Ian G Burwash; George A Wells; Ali Pourdjabbar; Trevor Simard; Harold Atkins; Christopher Glover Journal: CMAJ Date: 2014-06-16 Impact factor: 8.262
Authors: Buddhadeb Dawn; Ahmed Abdel-Latif; Santosh K Sanganalmath; Michael P Flaherty; Ewa K Zuba-Surma Journal: Antioxid Redox Signal Date: 2009-08 Impact factor: 8.401
Authors: Anush V Karapetyan; Yuri M Klyachkin; Samy Selim; Manjula Sunkara; Khaled M Ziada; Donald A Cohen; Ewa K Zuba-Surma; Janina Ratajczak; Susan S Smyth; Mariusz Z Ratajczak; Andrew J Morris; Ahmed Abdel-Latif Journal: Stem Cells Dev Date: 2013-02-19 Impact factor: 3.272